Fabrice Balavoine
6 Rue Cambacérès
Paris, 75008, France
Paris, 75008, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Rational design, synthesis and pharmacological characterization of novel aminopeptidase A inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: July 16, 2024
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions
Published: January 09, 2023
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.
Journal: The Canadian journal of cardiology
Published: June 24, 2021
Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 03, 2021
Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure.
Journal: The Canadian journal of cardiology
Published: January 31, 2020
NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: May 09, 2019
Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.
Journal: Circulation
Published: April 25, 2019
A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.
Journal: Journal of hypertension
Published: March 19, 2019
Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.
Journal: Journal of molecular and cellular cardiology
Published: August 09, 2018
Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats.
Journal: Journal of hypertension
Published: October 03, 2017
A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors.
Journal: Clinical science (London, England : 1979)
Published: April 05, 2014
Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.
Journal: Clinical pharmacokinetics
Published: December 17, 2013
Last Updated: 09/26/2026